FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978547119> ?p ?o ?g. }

• W2978547119 endingPage "v628" @default.
• W2978547119 startingPage "v627" @default.
• W2978547119 abstract "Abstract Background Treatment of EGFR mutation-positive NSCLC has been revolutionized with the development of EGFR tyrosine kinase inhibitors (TKIs). Three generations of TKIs are now available (1st: erlotinib, gefitinib; 2nd: afatinib, dacomitinib; 3rd: osimertinib). Osimertinib has been developed as second-line treatment after a first-line TKI 1G or 2G when patients progressed with T790M-positive tumors, the most frequent mechanism of resistance. While osimertinib may also be given as first-line treatment, limited data exists on the real life effectiveness of the TKIs sequencing approach: TKI 1G or 2G followed by osimertinib. The French National medico administrative claim database (SNDS) offers the opportunity to estimate the effectiveness parameters for these patients in France. Methods Based on SNDS, a historic cohort of patients with a diagnosis of EGFR-mutated NSCLC treated, after a first-line with a TKI 1G or 2G, with osimertinib in second-line between 2015 and 2017 was extracted. Follow-up was conducted until December 31st 2017. Patients’ characteristics, Time on treatments and Overall survival were analysed. Results 1,404 NSCLC patients have been treated with osimertinib in the database between 2015 and 2017. Among them, 509 had a previous treatment with TKI 1G or 2G without any other anticancer drug before osimertinib initiation, and constitute the analysed population. Mean age was 70.9 (29.1% were above 80 years old), 25.7% were males. Median time on TKI treatment (between the beginning of the first TKI 1G or 2G until discontinuation of osimertinib) was not reached but the percentages of patients still treated were: 83.8% at 24 months and 75.5% at 36 months. Median overall survival was not reached but the percentages of patients still alive were: 79.6% at 24 months and 70.3% at 36 months. Updated data will be presented at the meeting. Conclusions Our cohort confirms the prolonged time on TKI treatment and survival rates of patients receiving TKI 1G or 2G followed by osimertinib in a real life setting. Legal entity responsible for the study The authors. Funding Boehringer Ingelheim. Disclosure N. Girard: Honoraria (self): AstraZeneca; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): GlaxoSmithKline; Honoraria (self): Hoffmann La Roche; Honoraria (self): Lilly; Honoraria (self): Merck Sharp Dohme; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Takeda. S. Bouee: Full / Part-time employment: CEMKA. D. Moro-Sibilot: Honoraria (self), Honoraria (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Honoraria (institution): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Honoraria (institution): Roche; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self), Advisory / Consultancy: AbbVie. C. Emery: Full / Part-time employment, CEMKA received a grant from Boehringer Ingelheim to perform the statistical analysis of this study : CEMKA. K. Le Lay: Full / Part-time employment: Boehringer Ingelheim. L. Luciani: Full / Part-time employment: Boehringer Ingelheim. C. Maritaz: Full / Part-time employment: 4. Boehringer Ingelheim. C. Chouaid: Honoraria (self): AstraZeneca; Honoraria (self): Boehringer Ingelheim; Honoraria (self): GlaxoSmithKline; Honoraria (self): Roche; Honoraria (self): Sanofi; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Lilly; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Takeda; Honoraria (self): Bayer; Honoraria (self): Amgen." @default.
• W2978547119 created "2019-10-10" @default.
• W2978547119 creator A5006493520 @default.
• W2978547119 creator A5010700417 @default.
• W2978547119 creator A5016370905 @default.
• W2978547119 creator A5030455508 @default.
• W2978547119 creator A5035755766 @default.
• W2978547119 creator A5051357795 @default.
• W2978547119 creator A5052572685 @default.
• W2978547119 creator A5090329560 @default.
• W2978547119 date "2019-10-01" @default.
• W2978547119 modified "2023-09-23" @default.
• W2978547119 title "Effectiveness of sequencing TKIs in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC): A French national medical-administrative claim database analysis" @default.
• W2978547119 doi "https://doi.org/10.1093/annonc/mdz260.050" @default.
• W2978547119 hasPublicationYear "2019" @default.
• W2978547119 type Work @default.
• W2978547119 sameAs 2978547119 @default.
• W2978547119 citedByCount "0" @default.
• W2978547119 crossrefType "journal-article" @default.
• W2978547119 hasAuthorship W2978547119A5006493520 @default.
• W2978547119 hasAuthorship W2978547119A5010700417 @default.
• W2978547119 hasAuthorship W2978547119A5016370905 @default.
• W2978547119 hasAuthorship W2978547119A5030455508 @default.
• W2978547119 hasAuthorship W2978547119A5035755766 @default.
• W2978547119 hasAuthorship W2978547119A5051357795 @default.
• W2978547119 hasAuthorship W2978547119A5052572685 @default.
• W2978547119 hasAuthorship W2978547119A5090329560 @default.
• W2978547119 hasBestOaLocation W29785471191 @default.
• W2978547119 hasConcept C104317684 @default.
• W2978547119 hasConcept C121608353 @default.
• W2978547119 hasConcept C126322002 @default.
• W2978547119 hasConcept C143998085 @default.
• W2978547119 hasConcept C2776256026 @default.
• W2978547119 hasConcept C501734568 @default.
• W2978547119 hasConcept C54355233 @default.
• W2978547119 hasConcept C71924100 @default.
• W2978547119 hasConcept C86803240 @default.
• W2978547119 hasConceptScore W2978547119C104317684 @default.
• W2978547119 hasConceptScore W2978547119C121608353 @default.
• W2978547119 hasConceptScore W2978547119C126322002 @default.
• W2978547119 hasConceptScore W2978547119C143998085 @default.
• W2978547119 hasConceptScore W2978547119C2776256026 @default.
• W2978547119 hasConceptScore W2978547119C501734568 @default.
• W2978547119 hasConceptScore W2978547119C54355233 @default.
• W2978547119 hasConceptScore W2978547119C71924100 @default.
• W2978547119 hasConceptScore W2978547119C86803240 @default.
• W2978547119 hasLocation W29785471191 @default.
• W2978547119 hasOpenAccess W2978547119 @default.
• W2978547119 hasPrimaryLocation W29785471191 @default.
• W2978547119 hasRelatedWork W1575925512 @default.
• W2978547119 hasRelatedWork W1967103478 @default.
• W2978547119 hasRelatedWork W2032912323 @default.
• W2978547119 hasRelatedWork W2188259592 @default.
• W2978547119 hasRelatedWork W2372561159 @default.
• W2978547119 hasRelatedWork W2375344515 @default.
• W2978547119 hasRelatedWork W2390152934 @default.
• W2978547119 hasRelatedWork W3025817407 @default.
• W2978547119 hasRelatedWork W4206783359 @default.
• W2978547119 hasRelatedWork W4253419875 @default.
• W2978547119 hasVolume "30" @default.
• W2978547119 isParatext "false" @default.
• W2978547119 isRetracted "false" @default.
• W2978547119 magId "2978547119" @default.
• W2978547119 workType "article" @default.